Cipla Management Guidance Tracker

Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets.

Management increased full-year EBITDA margin guidance from 23% to 23-24%, with bias towards the higher end.

Full-year EBITDA margin trending at the higher end of the previously guided range of 23-24%.

Management expects EBITDA margin expansion of up to 100 bps over FY24's 24.5%, driven by cost measures and portfolio mix.

Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance.

Management reiterated full-year EBITDA margin guidance despite Q2 margin of 26.7%, expecting normalized Q3 and Q4.

EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.

Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss.

Management reiterated the full-year EBITDA margin range despite Q1 margin of 25.6% being above the range, citing potential Revlimid phasing and R&D investments.

Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution.

Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact.

Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2.

Cipla expects to file generic Symbicort (respiratory product) by the end of calendar year 2023.

Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period.

Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.

Cipla plans to file generic Symbicort in Q3 FY24, having completed clinical studies.

One peptide product launch planned in Q4 FY24, with 3-4 more in FY25.

Advair generic expected to be filed by mid-FY25 from an alternate site, with approval likely by end of next fiscal.

Four peptide launches planned in FY25, with one asset awaiting approval expected in Q1 FY25.

Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.

Targeting to launch four peptide assets during the fiscal year.

Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years.

ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.

Risking of generic Advair progressing as per expectations; launch targeted for first half of fiscal 2026.

Management expects India business to revert to growth trajectory with respiratory uptick in Q3 and outpace market growth for the full year.

Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected.

Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26).

Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.

Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.

COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.

Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.

Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.

Management expects strong double-digit and market-beating growth in India for FY27 and FY28.

Management guided US revenue of $220-225M as sustainable for the next quarter.

Aim to grow top line YoY, backed by commercial execution of existing portfolio and new launches.

Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits.

Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization.

Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.

CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.

Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.

Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.

Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches.

Capital investments planned to enhance manufacturing capability and sustainability.

Supply challenges expected to be resolved by end of Q3, with sharp recovery in lanreotide franchise from Q4 FY25.

Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway.

Management will provide FY27 guidance after finalizing the annual operating plan.

R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.

Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.